Protocols for the Evaluation of a Lymphatic Drug Delivery System Combined with Bioluminescence to Treat Metastatic Lymph Nodes

Overview

Journal Methods Mol Biol

Specialty Molecular Biology

Date 2022 Jul 13

PMID 35821485

Authors

Ariunbuyan Sukhbaatar

Tetsuya Kodama

Affiliations

Soon will be listed here.

Abstract

Bioluminescence (BL) imaging is a powerful non-invasive imaging modality widely used in a broad range of biological disciplines for many types of measurements. The applications of BL imaging in biomedicine are diverse, including tracking bacterial progression, research on gene expression patterns, monitoring tumor cell growth/regression or treatment responses, determining the location and proliferation of stem cells, and so on. It is particularly valuable when studying tissues at depths of 1 to 2 cm in mouse models during preclinical research. Here we describe the protocols for the therapeutic evaluation of a lymphatic drug delivery system (LDDS) using an in vivo BL imaging system (IVIS) for the treatment of metastatic lymph nodes (LNs) with 5-fluorouracil (5-FU). The LDDS is a method that directly injects anticancer drugs into sentinel LNs (SLNs) and delivers them to their downstream LNs. In the protocol, we show that metastases in the proper axillary LN (PALN) are induced by the injection of luciferase-expressing tumor cells into the subiliac LN (SiLN) of MXH10/Mo-lpr/lpr (MXH10/Mo/lpr) mice. 5-FU is injected using the LDDS into the accessory axillary LN (AALN) to treat tumor cells in the PALN after the tumor cell growth is confirmed in the PALN. The tumor growth and therapeutic effects are evaluated by IVIS. This method can be used to evaluate tumor growth and efficacy of anticancer drugs/particles, radiotherapy, surgery, and/or a combination of these methods in various experimental procedures in the oncology field.

References

Levin M, Bjornheden T, Evaldsson M, Walenta S, Wiklund O . A bioluminescence method for the mapping of local ATP concentrations within the arterial wall, with potential to assess the in vivo situation. Arterioscler Thromb Vasc Biol. 1999; 19(4):950-8. DOI: 10.1161/01.atv.19.4.950. View

Rehemtulla A, Stegman L, Cardozo S, Gupta S, Hall D, Contag C . Rapid and quantitative assessment of cancer treatment response using in vivo bioluminescence imaging. Neoplasia. 2001; 2(6):491-5. PMC: 1508085. DOI: 10.1038/sj.neo.7900121. View

Hoffman R . Visualization of GFP-expressing tumors and metastasis in vivo. Biotechniques. 2001; 30(5):1016-22, 1024-6. DOI: 10.2144/01305bi01. View

Contag C, Bachmann M . Advances in in vivo bioluminescence imaging of gene expression. Annu Rev Biomed Eng. 2002; 4:235-60. DOI: 10.1146/annurev.bioeng.4.111901.093336. View

Sato A, Klaunberg B, Tolwani R . In vivo bioluminescence imaging. Comp Med. 2005; 54(6):631-4. View

Kim J, Kalimuthu S, Ahn B . In vivo cell tracking with bioluminescence imaging. Nucl Med Mol Imaging. 2015; 49(1):3-10. PMC: 4354780. DOI: 10.1007/s13139-014-0309-x. View

Gutowski M, Wilson L, Van Gelder R, Pepple K . In Vivo Bioluminescence Imaging for Longitudinal Monitoring of Inflammation in Animal Models of Uveitis. Invest Ophthalmol Vis Sci. 2017; 58(3):1521-1528. PMC: 5361579. DOI: 10.1167/iovs.16-20824. View

Mezzanotte L, van t Root M, Karatas H, Goun E, Lowik C . In Vivo Molecular Bioluminescence Imaging: New Tools and Applications. Trends Biotechnol. 2017; 35(7):640-652. DOI: 10.1016/j.tibtech.2017.03.012. View

Vogel S, Collmann F, Hoehn M . Perspectives of In Vivo Bioluminescence Imaging: Application to Basic and Translational Neuroscience. Curr Pharm Des. 2016; 23(13):1963-1973. DOI: 10.2174/1381612822666161226151811. View

10.

Fujii H, Horie S, Sukhbaatar A, Mishra R, Sakamoto M, Mori S . Treatment of false-negative metastatic lymph nodes by a lymphatic drug delivery system with 5-fluorouracil. Cancer Med. 2019; 8(5):2241-2251. PMC: 6536938. DOI: 10.1002/cam4.2125. View

11.

Mikada M, Sukhbaatar A, Miura Y, Horie S, Sakamoto M, Mori S . Evaluation of the enhanced permeability and retention effect in the early stages of lymph node metastasis. Cancer Sci. 2017; 108(5):846-852. PMC: 5448659. DOI: 10.1111/cas.13206. View

12.

Tada A, Horie S, Mori S, Kodama T . Therapeutic effect of cisplatin given with a lymphatic drug delivery system on false-negative metastatic lymph nodes. Cancer Sci. 2017; 108(11):2115-2121. PMC: 5666029. DOI: 10.1111/cas.13387. View

13.

Ouchi T, Sukhbaatar A, Horie S, Sakamoto M, Shiga K, Mori S . Superselective Drug Delivery Using Doxorubicin-Encapsulated Liposomes and Ultrasound in a Mouse Model of Lung Metastasis Activation. Ultrasound Med Biol. 2018; 44(8):1818-1827. DOI: 10.1016/j.ultrasmedbio.2018.04.003. View

14.

Shao L, Mori S, Yagishita Y, Okuno T, Hatakeyama Y, Sato T . Lymphatic mapping of mice with systemic lymphoproliferative disorder: usefulness as an inter-lymph node metastasis model of cancer. J Immunol Methods. 2013; 389(1-2):69-78. DOI: 10.1016/j.jim.2013.01.004. View

15.

Shao L, Takeda K, Kato S, Mori S, Kodama T . Communication between lymphatic and venous systems in mice. J Immunol Methods. 2015; 424:100-5. DOI: 10.1016/j.jim.2015.05.007. View

16.

Van Den Broeck W, Derore A, Simoens P . Anatomy and nomenclature of murine lymph nodes: Descriptive study and nomenclatory standardization in BALB/cAnNCrl mice. J Immunol Methods. 2006; 312(1-2):12-9. DOI: 10.1016/j.jim.2006.01.022. View